Pay in 4 interest-free payments of $6.55 Learn more
Ships within 48 hours · Estimated delivery Oct 6 - Oct 11
Reported effects in human use are generally mild injection-site reactions, fatigue, head rush or lightheadedness shortly after a dose
Missy says, Growing up in California, I was always aware of natural health and lifestyles, but it wasnt until I became very sick and healed many of my personal ailments that I decided to go back to school
BENEFITS Triple receptor activation studied for simultaneous GLP-1, GIP, and glucagon engagement Metabolic research explored in Phase 2 clinical trials with notable body-composition results Glucagon component linked to thermogenesis and energy-expenditure pathways Next-generation compound investigated as an advancement over dual-agonist approaches Comparative pharmacology assessed alongside mono- and dual-agonists in research settings WHAT RESEARCHERS LOOK AT Triple-agonist binding affinity across GLP-1, GIP, and glucagon receptors Additive effects of glucagon-receptor activation on energy expenditure Dose-response and tolerability profiling from clinical-trial data Comparative outcomes vs tirzepatide and semaglutide Pharmacokinetic profiling and receptor selectivity QUICK SPECS Form: Lyophilized peptide powder Net per vial: 10 mg Purity: 99% (HPLC verified) Identity: MS-verified (per COA) Storage: 28C, protect from light and moisture Reconstitution: Use bacteriostatic water (sold separately) IDENTITY BASICS CAS: 2381089-83-2 Classification: Triple GLP-1/GIP/glucagon receptor agonist WHY CHOOSE DURHAM PEPTIDES FOR RETATRUTIDE
Now we know that it engages a complex, body-wide network that connects the digestive, vascular, nervous, and immune systems
Reported effects below derive from the published preclinical and in vitro literature on the individual components not from human clinical trials of the KLOW blend specifically
US$ 22.81
US$ 26.33
US$ 22.79
US$ 27.25
US$ 28.97
